Grant List
Represents Grant table in the DB
GET /v1/grants?page%5Bnumber%5D=1392&sort=end_date
{ "links": { "first": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1&sort=end_date", "last": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1424&sort=end_date", "next": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1393&sort=end_date", "prev": "https://cic-apps.datascience.columbia.edu/v1/grants?page%5Bnumber%5D=1391&sort=end_date" }, "data": [ { "type": "Grant", "id": "14704", "attributes": { "award_id": "1K23EY035741-01", "title": "Artificial Intelligence Analysis of Myopic Vitreoretinal Pathology", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Eye Institute (NEI)" ], "program_reference_codes": [], "program_officials": [ { "id": 31398, "first_name": "EDWIN C", "last_name": "Clayton", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-03-01", "end_date": "2029-02-28", "award_amount": 274148, "principal_investigator": { "id": 31399, "first_name": "Cassie Ann", "last_name": "Ludwig", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 266, "ror": "https://ror.org/00f54p054", "name": "Stanford University", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "PROJECT SUMMARY: This application seeks a career development award for an academic vitreoretinal surgeon with an interest in high myopia, a condition which predisposes patients to potentially blinding complications including retinal tears (RTs) and rhegmatogenous retinal detachments (RRDs). This proposal is a 5-year curriculum and research plan to transition Dr. Cassie Ludwig to independence. The candidate is an accomplished early career physician-scientist who will undergo all training and execute the research noted herein during this period. Myopia affects one third of the world's population today and has been predicted to affect 50% of the world's population by 2050.1,2 Worse, this prediction is likely an underestimate as myopigenic behaviors have been further compounded by the COVID pandemic and digital remote learning.3–8 This increasing prevalence has significant consequences as each diopter of myopia increases the risk of retinal tears and detachments, myopic macular degeneration, choroidal neovascularization, myopic traction maculopathy, strabismus, glaucoma, and cataracts. Slowing myopia progression even minimally can help prevent blindness. Using combined data from five large population-based studies, Bullimore et al. found that slowing myopia by one diopter should reduce the likelihood of a patient developing an RRD by 30%.2 Electronic health records (EHRs) and ophthalmic imaging databases contain enormous quantities of systemic and ocular data generated by clinical practice which can be used to better understand the relationship between systemic and ophthalmic risk factors, myopia and RTs and RRDs. EHR and imaging data can be fused into predictive models that employ machine learning to risk-stratify patients. In this proposal, Dr. Ludwig aims to achieve the following: 1. Develop and validate a structured EHR deep learning framework to predict RT and RRD risk in myopes and non-myopes 2. Develop and validate an unstructured EHR transformer-based deep learning model to predict RT and RRD risk in myopes and non-myopes, and 3. Develop and validate an ultra-widefield photography convolutional neural network (CNN)-based deep learning model to predict RT and RRD risk in myopes and non-myopes. The central hypothesis is that modeling of attributes from EHR data and images can predict risk of RTs and RRDs. The principal investigator, Cassie A. Ludwig, MD, MS, will perform this research as part of a larger effort to obtain additional training and mentorship in biomedical informatics, artificial intelligence, biodesign, and myopia. Dr. Ludwig’s career development plan includes a PhD program with didactic coursework, conferences, workshops, and frequent communication and interaction with a network of mentors with an impressive abundance of their own NIH funding and prior mentorship experiences. This experience will guide Dr. Ludwig into a career as an independent clinician-scientist with expertise in artificial intelligence and a focus on myopia and its sequelae.", "keywords": [ "Affect", "Algorithms", "Artificial Intelligence", "Behavior", "Bioinformatics", "Blindness", "COVID-19 pandemic", "Cataract", "Choroidal Neovascularization", "Clinical", "Code", "Color", "Communication", "Cornea", "Data", "Databases", "Development Plans", "Diabetic Retinopathy", "Diagnosis", "Disease", "Distance Learning", "Doctor of Philosophy", "Educational Curriculum", "Educational workshop", "Electronic Health Record", "Faculty", "Funding", "Fundus photography", "Glaucoma", "Goals", "Image", "K-Series Research Career Programs", "Knowledge", "Length", "Light", "Link", "Logistic Regressions", "Machine Learning", "Macular degeneration", "Mentors", "Mentorship", "Methodology", "Methods", "Modeling", "Myopia", "Natural Language Processing", "Optical Coherence Tomography", "Outcome", "Pathologic", "Pathology", "Patients", "Photography", "Physicians", "Population", "Population Study", "Prevalence", "Prevention", "Principal Investigator", "Prophylactic treatment", "Provider", "Radiology Specialty", "Reporting", "Research", "Retina", "Retinal Detachment", "Retinal Diseases", "Retinal Perforations", "Risk", "Risk Factors", "Scientist", "Sensitivity and Specificity", "Statistical Methods", "Strabismus", "Structure", "Surgeon", "Symptoms", "Testing", "Text", "Thick", "Traction", "Training", "United States National Institutes of Health", "Validation", "Vision", "Visual", "artificial intelligence algorithm", "biomedical informatics", "career", "career development", "clinical encounter", "clinical practice", "cohort", "convolutional neural network", "deep learning", "deep learning model", "deep neural network", "demographics", "digital", "disorder of macula of retina", "electronic structure", "experience", "high risk", "improved", "interest", "machine learning model", "ophthalmic examination", "patient stratification", "predictive modeling", "prevent", "programs", "prophylactic", "repaired", "retinal imaging", "risk prediction", "risk stratification", "standard of care", "symposium", "training opportunity", "vitreous floater" ], "approved": true } }, { "type": "Grant", "id": "14708", "attributes": { "award_id": "1U01AI179524-01", "title": "Systems analyses of induction and maintenance of immunity to SARS-CoV-2 vaccination in kidney transplant recipients receiving mycophenolate mofetil immunotherapy", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 6717, "first_name": "Conrad M.", "last_name": "Mallia", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-03-01", "end_date": "2029-02-28", "award_amount": 605731, "principal_investigator": { "id": 23198, "first_name": "ELAINE F", "last_name": "REED", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [ { "id": 818, "ror": "", "name": "UNIVERSITY OF CALIFORNIA LOS ANGELES", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true } ] }, "other_investigators": [], "awardee_organization": { "id": 818, "ror": "", "name": "UNIVERSITY OF CALIFORNIA LOS ANGELES", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Immunocompromised patients, including those requiring immunosuppressive therapy following organ transplantation, are at high risk for severe disease from SARS‐CoV‐2. As SARS-CoV-2 rapidly transitions from a pandemic virus to endemic status, like influenza, seasonal vaccinations against emerging variants will likely become the primary tool for limiting morbidity and mortality. While the efficacy of vaccination against SARS-CoV- 2 has been very promising, specific populations have been identified who are at increased risk of failing to develop protective immunity. Immunocompromised populations respond poorly to SARS-CoV-2 vaccination, particularly solid organ transplant (SOT) recipients receiving immunosuppressive therapy. Within SOT recipients, the type and dose of immunosuppressive therapy have further been shown to impact vaccine efficacy. Patients receiving mycophenolate mofetil (MMF) immunotherapy, which functions by preventing B and T cell proliferation/activation, as well as leukocyte recruitment, have the poorest humoral and cellular response post- vaccination for SARS-CoV-2. Preliminary evidence suggests that discontinuing MMF before vaccination improves humoral responses in SOT recipients. This project will test the hypothesis that coordinated innate and adaptive dysregulation pre-vaccination driven by MMF immunosuppressive therapy diminishes the quality, quantity, and durability of cellular and humoral immunity to SARS-CoV-2 in kidney transplant recipients. In Aim 1, we will characterize the impact of MMF on the generation, quality, and maintenance of adaptive immune responses to SARS-CoV-2 vaccination in SOT recipients. We will use validated assays to quantify and functionally profile humoral and cellular immunity to SARS-CoV-2. In Aim 2, we will define the pre-vaccine immunological determinants of a protective host immune response to SARS-CoV-2 vaccination in kidney transplant recipients and identify the mechanisms of MMF-diminished immunity. We will use systems biological tools to comprehensively profile, at the single-cell level, the peripheral immune system prior to vaccination. In Aim 3, we will determine how pre-vaccine MMF reduction impacts the host immune response to SARS-CoV-2 booster vaccination in kidney transplant recipients. Together, these data will provide a comprehensive, mechanistic understanding of how MMF immunotherapy dysregulates the immune system in SOT recipients and how this dysregulation impacts the induction and durability of protective immunity against SARS-CoV-2. This knowledge will allow the development of targeted strategies to correct or circumvent MMF-driven immune dysregulation, thereby permitting efficacious responses to SARS-CoV-2, and other vaccines, in SOT recipients and other at-risk populations.", "keywords": [ "2019-nCoV", "Acute", "Address", "Antibodies", "Antibody titer measurement", "B-Lymphocytes", "Biological Assay", "COVID-19 booster", "COVID-19 vaccination", "Cells", "Cellular Immunity", "Clinical", "Clinical Trials", "Computer Models", "DNA Methylation", "Data", "Development", "Disease", "Dose", "Effectiveness", "Enrollment", "General Population", "Generations", "Goals", "Humoral Immunities", "Immune", "Immune System Diseases", "Immune response", "Immune system", "Immunity", "Immunocompromised Host", "Immunologics", "Immunosuppressive Agents", "Immunotherapy", "Impairment", "Individual", "Infection", "Influenza", "Kidney Transplantation", "Knowledge", "Leukocytes", "Maintenance", "Methods", "Morbidity - disease rate", "Organ Transplantation", "Patients", "Peripheral", "Peripheral Blood Mononuclear Cell", "Persons", "Pharmaceutical Preparations", "Phase", "Plasma", "Population", "Populations at Risk", "Research", "Risk", "SARS-CoV-2 antibody", "SARS-CoV-2 immunity", "Seasons", "Secondary Immunization", "Severe Acute Respiratory Syndrome", "Solid", "Systems Analysis", "T cell response", "T-Cell Proliferation", "Testing", "Therapeutic immunosuppression", "Transplant Recipients", "Vaccination", "Vaccines", "Variant", "Virus", "adaptive immune response", "biological systems", "high risk", "improved", "methylation pattern", "mortality", "mycophenolate mofetil", "organ transplant recipient", "pandemic disease", "pandemic virus", "prediction algorithm", "predictive signature", "prevent", "recruit", "response", "tool", "vaccination strategy", "vaccine efficacy", "vaccine response" ], "approved": true } }, { "type": "Grant", "id": "14816", "attributes": { "award_id": "1R01HL173537-01", "title": "An Integrated Host-Microbe Gene Classifier to Predict SARS-CoV-2 and Severe Disease in Children with Respiratory Viral Coinfections", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 23102, "first_name": "Aruna R.", "last_name": "Natarajan", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-06-01", "end_date": "2029-02-28", "award_amount": 694403, "principal_investigator": { "id": 31495, "first_name": "Joshua", "last_name": "Kennedy", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1427, "ror": "", "name": "ARKANSAS CHILDREN'S HOSPITAL RES INST", "address": "", "city": "", "state": "AR", "zip": "", "country": "United States", "approved": true }, "abstract": "Respiratory viral coinfections (RVCIs) are more common in children than adults and have become increasingly important due to the emergence of SARS-COV-2. However, the distinction between coinfection and codetection remains unclear. Further, the association between finding multiple viruses using our current clinical methods and the effect on clinical outcomes is nebulous. Understanding positive viral testing has become crucial with the ongoing spread of SARS-CoV-2 and the treatment algorithms that are expensive or deleterious to patients with other viruses. Currently, clinicians struggle to identify the dominant virus inducing the host immune response in RVCIs in children. Our group has developed gene classifiers to identify adults with SARS-CoV-2 compared to other viruses using nasopharyngeal swabs. Further, we are the first to develop a host/microbe classifier for pediatric patients on the ventilator that will distinguish lower respiratory tract infections using lower airway sampling. Here, our objective is to identify patient features, coinfecting viruses, microbial contributions, and host responses that enhance disease severity in SARS-CoV-2–infected children. As the only pediatric hospital in the state, Arkansas Children's Hospital is an ideal site for studying SARS-CoV-2 RVCIs. We aim to leverage our unique multi-institutional collaborative team with extensive experience applying metagenomic next-generation sequencing to simultaneously evaluate viral and host genetic material from clinically obtained nasopharyngeal specimens. This approach identifies host–virus interactions and allows us to assess their impact on immune responses and disease severity during RVCIs. We hypothesize that a combination of patient characteristics, viral features, and host immune responses will predispose a child to more severe disease. We also expect to identify an immunologic fingerprint for SARS-CoV-2 that can be used to identify it as the “infecting virus” in children with codetections. The impact of this study is significant, and the multidisciplinary team that this proposal brings together is experienced. By employing epidemiologic, -omic, and computational approaches, we will identify immunologic fingerprints of SARS-CoV-2 infections in children, which can help identify the “infecting virus” when multiple viruses are detected. Further, this study will provide distinction regarding the clinical implications of codetections of viruses, including SARS-CoV-2, in children. The findings will support future clinical trials evaluating treatment options based on the immunologic fingerprints that we identify.", "keywords": [ "2019-nCoV", "5 year old", "Acute respiratory infection", "Adult", "Affect", "Age", "Algorithms", "Area Under Curve", "Arkansas", "COVID-19 treatment", "Characteristics", "Child", "Clinical", "Clinical Trials", "Data", "Disease", "Enterovirus", "Epidemiology", "Ethnic Origin", "Fingerprint", "Future", "Gender", "Gene Expression", "Genes", "Genetic Materials", "Immune System Diseases", "Immune response", "Immunologics", "Immunomodulators", "Individual", "Infection", "Institution", "Knowledge", "Laboratories", "Lower Respiratory Tract Infection", "Metagenomics", "Methods", "Microbe", "Modeling", "Monoclonal Antibodies", "Nasopharynx", "Outcome", "Pathogenicity", "Patients", "Pediatric Hospitals", "Prevention", "Prognosis", "Race", "Recording of previous events", "Research Personnel", "Respiratory Syncytial Virus Infections", "Respiratory syncytial virus", "Rhinovirus", "Risk", "SARS-CoV-2 infection", "SARS-CoV-2 variant", "Sampling", "Severe Acute Respiratory Syndrome", "Severities", "Severity of illness", "Site", "Specimen", "Steroids", "Symptoms", "Testing", "Vaccination", "Ventilator", "Viral", "Virus", "Virus Diseases", "World Health Organization", "clinical material", "co-infection", "comorbidity", "experience", "improved", "improved outcome", "interest", "microbial", "multidisciplinary", "nasopharyngeal swab", "next generation sequencing", "novel", "pathogenic microbe", "pediatric patients", "pediatrician", "predictive modeling", "respiratory", "respiratory pathogen", "severe COVID-19", "targeted therapy trials", "targeted treatment", "tocilizumab", "viral detection", "virus host interaction", "virus testing" ], "approved": true } }, { "type": "Grant", "id": "14899", "attributes": { "award_id": "1R01AG083464-01A1", "title": "Identifying salient factors that influence physician practices in mitigating patient misinformation", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Aging (NIA)" ], "program_reference_codes": [], "program_officials": [ { "id": 8342, "first_name": "Marcel", "last_name": "Salive", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-06-15", "end_date": "2029-02-28", "award_amount": 729380, "principal_investigator": { "id": 31587, "first_name": "Zubin", "last_name": "Master", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 1149, "ror": "", "name": "WAKE FOREST UNIVERSITY HEALTH SCIENCES", "address": "", "city": "", "state": "NC", "zip": "", "country": "United States", "approved": true }, "abstract": "Medical misinformation is a global health problem with 73% of US adults having been exposed to false health information and 87% expressing concern about it. Health misinformation can hijack a patient’s typical discernment faculties and can lead to poor health outcomes. Evidence shows that elderly patients are disproportionately affected by health misinformation and are more likely to believe and spread misinformation, and suffer negative consequences. Engaging physicians has been touted as a promising and plausible means to mitigate misinformation because they are highly trusted, routinely provide reliable medical information, and are effective at influencing sustainable behavior change. Yet there is virtually no empirical data about physician misinformation corrective practices. Physician practices to correct patient misinformation is likely to depend on their political and religious beliefs as seen in other health areas, familiarity with the topic, correction and communication skills, self-efficacy, and environmental (e.g., time) and interpersonal factors (e.g., exhaustion). Prior to developing scalable and evidence-based physician communication interventions, a rich assessment of factors that facilitate or impede physician corrective practices is needed. We use a mixed-methods approach to identify factors and the strength of association among barriers/facilitators and physician willingness to correct misinformation through three specific aims using two divergent cases: unproven stem cell therapies and Covid- 19 vaccination. In Aim 1, we will interview primary care physicians to assess knowledge, experience, attitudes, and beliefs about correcting misinformation. In Aim 2, we will create a novel Determinants of Willingness to Correct Misinformation (DWCM) measure based on Aim 1 qualitative data, expert review, cognitive interviews, and psychometrically evaluate dimensionality and internal consistency. A national survey of physicians using the validated DWCM instrument will be conducted to measure determinants that impact physician corrective practices and attitudes towards adopting a priori correction strategies in their practice. In Aim 3, we will conduct online asynchronous focus groups with elderly patients across the US to assess receptivity towards corrective information from physicians, communication comprehension, channel preferences, and affect towards receiving corrective information and the use of specific terminology. Upon completing this research, we will have (i) identified major factors and their association with physician misinformation corrective practices and their attitudes towards adopting corrective strategies; (ii) created a valid DWCM climate instrument that can be deployed in different health care environments; (iii) offered data into patient receptivity towards receiving corrective information from physicians, including modes of exchange and appropriate language, and (iv) be well-positioned to develop and test the efficacy of a misinformation correction toolkit for physicians in future research.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15264", "attributes": { "award_id": "1R01MD019749-01", "title": "Motivate, Vaccinate, Activate’: An effectiveness-implementation trial to assess the impact of a multi-component community-based intervention to increase RSV vaccine uptake among Latino older adults", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute on Minority Health and Health Disparities (NIMHD)" ], "program_reference_codes": [], "program_officials": [ { "id": 6029, "first_name": "JARRETT AINSWORTH", "last_name": "Johnson", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-08-26", "end_date": "2029-02-28", "award_amount": 686134, "principal_investigator": { "id": 31852, "first_name": "Carina", "last_name": "Marquez", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 768, "ror": "https://ror.org/043mz5j54", "name": "University of California, San Francisco", "address": "", "city": "", "state": "CA", "zip": "", "country": "United States", "approved": true }, "abstract": "Respiratory Syncytial Virus (RSV) causes a substantial burden of hospitalizations and deaths among older adults, comparable to that of influenza. The new and effective RSV vaccines have the potential to dramatically reduce RSV morbidity and mortality, yet their full public health impact will not be realized if the racial and ethnic disparities in RSV vaccine uptake mirror those observed in other respiratory virus-vaccines, from COVID-19 to influenza. We have the opportunity to adapt community-based interventions from the COVID-19 pandemic to proactively address disparities in RSV vaccine uptake. However, evidence-based data, conducted in partnership with impacted communities, are essential. This project will focus on increasing RSV vaccine uptake among Latinos, a community disproportionatly affected by respiratory vaccines and RSV. We will leverage our well-established community-academic partnership, Unidos en Salud, to adapt two components of our ‘Motivate, Vaccinate, Activate’ intervention— CHW counseling and text message nudges. This multi-component intervention was originally designed to increase COVID-19 vaccine uptake among Latinos and to activate people to recommend vaccination to people in one’s social network. Our overall study objective is to adapt this intervention to inform effective and customizable community-based strategies to increase RSV vaccine uptake. In addition to a rigorous randomized trial design, we will collect detailed implementation outcomes to aide in generalizability and adaption to other vaccines and settings. Our primary hypothesis is that language-and culturally-concordant CHW motivation and activation counseling sessions, coupled with text message nudges, will increase RSV vaccine confidence by adressing trust, knowledge, and access-related barriers. The proposed study has three aims. In Aim 1 we will use the ADAPT-IT framework to adapt two intervention components: CHW counseling and text-message nudges to increase RSV vaccine uptake among Latino older adults (>60 years) (Aim 1a) and enable younger adults (18-50 years old) to discuss RSV vaccination with older adults in their social and family networks (Aim 1b). Then in Aim 2 we will conduct a two-arm type-1 effectiveness implementation trial to determine the effectiveness and implementation of a CHW counseling and text-message intervention on RSV vaccine uptake in Latino adults >60 years. In Aim 3, using a parallel trial design and social network analytic techniques, we will test the effectiveness of CHW counseling and text-message nudges on activating Latino adults to discuss RSV vaccination with the older adults within their social networks. The proposed work will provide timely, rigorous, and adaptable data to directly inform community-based approaches to increase RSV vaccination. In addition to providing timely data to reduce RSV vaccine disparities, these data will also advance our scientific understanding of the effectiveness of text-messages from community-based organizations and community-based interventions aimed at activating cross-generational social networks to boost vaccine uptake.", "keywords": [], "approved": true } }, { "type": "Grant", "id": "15608", "attributes": { "award_id": "1R01EB037025-01", "title": "Synthetic RNA Switch-Based Temporal and Dose Control of in Vivo Gene Therapies", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Biomedical Imaging and Bioengineering (NIBIB)" ], "program_reference_codes": [], "program_officials": [ { "id": 28204, "first_name": "NICHOLE MARIE", "last_name": "Daringer", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-03-01", "end_date": "2029-02-28", "award_amount": 540524, "principal_investigator": { "id": 32104, "first_name": "Guocai", "last_name": "Zhong", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 790, "ror": "", "name": "UNIV OF MASSACHUSETTS MED SCH WORCESTER", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "One-time in vivo gene therapies, based on adeno-associated viral (AAV) vector delivery of genes encoding therapeutic proteins, noncoding RNAs, or genome/epigenome editors, may provide long-lasting (years of, or even lifelong) treatments or cures for many rare and common diseases. However, we cannot currently tune or inactivate transgene expression to reflect disease progression or the emergence of adverse events or contraindications over time, limiting the utility of AAV gene therapies. The constrained packaging capacity of AAV vectors (~4.7 kb) has thwarted development of genetic switches that can regulate transgene expression timing or levels—the solution to these limitations. To date, just a few AAV-compatible switches function in animals. Typically, these switches are activated or repressed by ligands with undesirable side effect, including rapamycin, a potent immune suppressant; tetracycline, an antibiotic not suitable for chronic use; and branaplam, a compound that causes peripheral neurotoxicity. We previously engineered an efficient synthetic RNA ON switch based on our novel self-cleaving ribozyme T3H38, which is regulated by a complementary morpholino oligonucleotide. At 63 bp long, the tiny T3H38 ribozyme can be inserted into the 3′ UTR of a transgene. Its regulator, a 25 nt morpholino oligo is part of a class of chemically modified RNA drugs that have proven safe for chronic use in humans. The T3H38 ribozyme showed a ~200-fold regulation in AAV transgene expression in mice upon administration of the complementary morpholino oligo to the animals. Optimizing the T3H38 ribozyme switch towards a leak-free system with no detectable baseline transgene expression in the absence of the morpholino oligo could transform AAV-based gene therapy. For example, it can enable safe use of AAV to express a variety of transgenes with narrow therapeutic windows (e.g., cytokines, hormones, genome editors), where an overdose or prolonged exposure can cause severe adverse events, or to conditionally express therapeutics with major contraindications (e.g., cytokines), specific disease conditions where a drug should not be used or should be discontinued. In preliminary studies, we have developed an enhanced RNA ON switch (regulatory range: up to 35,000-fold in mice) based on the T3H38 ribozyme. Here, we will (i) optimize the enhanced RNA switch to engineer an ultra-efficient switch with negligible leakiness; (ii) use the optimized switch for precise dose control of an AAV expressing erythropoietin—a paradigmatic biologic with a short half-life, a narrow therapeutic window, and major contraindications—for the treatment of chronic Epo-deficient anemia in a mouse model; and (iii) further optimize the switch system in mouse airways for temporal control of an AAV expressing a broadly anti-coronavirus immunoadhesin—a prototype of a broadly effective prophylaxis for immunocompromised individuals against a panel of coronaviruses of pandemic potential. The completion of this project will provide a broadly useful and potentially transformative regulatable gene therapy technology and proofs of concept showcasing the utility of this technology.", "keywords": [ "3&apos", "Untranslated Regions", "ACE2", "Adverse effects", "Adverse event", "Anemia", "Animals", "Antibiotics", "Biological", "Biological Products", "COVID-19", "Catalytic RNA", "Cell Culture Techniques", "Chemicals", "Chronic", "Circulation", "Communicable Diseases", "Coronavirus", "Development", "Devices", "Disease", "Disease Progression", "Dose", "Duchenne muscular dystrophy", "Ebola", "Engineering", "Episome", "Erythropoietin", "Friends", "Gene Delivery", "Gene Expression", "Genetic", "Genome", "Goals", "HIV Infections", "Half-Life", "Hormones", "Human", "Immune", "Immunocompromised Host", "Individual", "Interphase Cell", "Kinetics", "Ligands", "Luciferases", "Mediating", "Mus", "Muscle", "Oligonucleotides", "Overdose", "Peripheral", "Pharmaceutical Preparations", "Prophylactic treatment", "Proteins", "RNA", "Regulation", "Reporter", "Repression", "SARS-CoV-2 infection", "SARS-CoV-2 variant", "Safety", "Serious Adverse Event", "Sirolimus", "Somatic Cell", "System", "Technology", "Tetracyclines", "Therapeutic", "Time", "Transgenes", "Untranslated RNA", "Viral", "Viral Genes", "Viral Vector", "adeno-associated viral vector", "adenovirus mediated delivery", "cytokine", "epigenome", "expression vector", "feasibility testing", "gene therapy", "genome editor", "high risk population", "human disease", "improved", "in vivo", "mouse model", "neurotoxicity", "neutralizing antibody", "novel", "pandemic coronavirus", "prototype", "rare genetic disorder", "receptor", "side effect", "therapeutic protein", "transgene expression" ], "approved": true } }, { "type": "Grant", "id": "15685", "attributes": { "award_id": "1R01HL174310-01A1", "title": "Multi-scale characterization of antigen-polymerized immune complexes underlying thrombotic pathologies triggered by adenoviral-vectored vaccines", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 32532, "first_name": "RONALD Q", "last_name": "WARREN", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-05-01", "end_date": "2029-02-28", "award_amount": 601677, "principal_investigator": { "id": 32533, "first_name": "IGOR A", "last_name": "KALTASHOV", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 200, "ror": "https://ror.org/0072zz521", "name": "University of Massachusetts Amherst", "address": "", "city": "", "state": "MA", "zip": "", "country": "United States", "approved": true }, "abstract": "Immunothrombosis is a critical element of intravascular immunity, but its dysregulation or malfunction leads to a range of thrombotic disorders including stroke and disseminated intravascular coagulation. The massive vaccination campaign during the recent COVID-19 pandemic brought to light a novel immunothrombotic pathology, a relatively rare but extremely dangerous side effect of adenoviral (Ad) vectored vaccines, which is now known as vaccine-induced immune thrombotic thrombocytopenia (VITT). Although COVID-19 is no longer a global health threat, the close association of VITT with a specific delivery vector raises the specter of other Ad- vectored vaccines also eliciting this deadly side effect, a grave prospect given the popularity of this platform. VITT has been linked to the emergence of autoantibodies recognizing a cognate chemokine, platelet factor 4 (PF4), but the specific mechanism underlying this pathology remains elusive. Understanding its molecular mechanism and etiology is critical for addressing the currently unmet need to design rational therapeutic and prophylactic strategies targeting VITT. It will also go a long way towards filling the gaps in understanding the delicate interplay between the beneficial and deleterious effects of immunothrombosis and provide the urgently needed ammunition to suppress the latter without sacrificing the former. We will use a combination of experimental and modeling tools to study VITT emergence and progression on different scales, ranging from micro- (formation of platelet-activating immune complexes) to macroscale (thrombi formation). We have already obtained a complete amino acid sequence of the pathogenic VITT antibody and produced its recombinant copy (RVT1) in quantities sufficient for both biophysical and biological investigations. On the microscale, we will use mass spectrometry and other biophysical tools to study the architecture and biological properties of the immune complexes composed of PF4 and RVT1. On the macro-scale, we will use these complexes to study thrombi initiation and formation using in vitro models based on microfluidic devices mimicking vascular environments relevant for VITT pathogenesis (e.g., cerebral venous vasculature). Bridging the micro- and macro-scales will allow us to elucidate the detailed mechanism of VITT progression by understanding how the disease outcome is modulated by the physical and biochemical properties of its molecular triggers. It will also provide a unique opportunity to address another enigmatic feature of VITT - its frequent localization within the cerebral venous sinuses. Lastly, correlating the amino acid sequences of the pathogenic antibodies and the germline sequences for a set of VITT patients will reveal the etiology of this disease, enabling the design of effective prophylactic and monitoring strategies. The proposed research will be carried out by an interdisciplinary team comprising chemists and biophysicists (Dr. Kaltashov's lab at UMass-Amherst), hematologists and molecular biologists (Dr. Nazy's lab at McMaster University School of Medicine) and biomedical engineers (Dr. Jiménez' lab at UMass-Amherst).", "keywords": [ "Address", "Adenovirus Vector", "Adenoviruses", "Amino Acid Sequence", "Antibodies", "Antigen-Antibody Complex", "Antigens", "Architecture", "Autoantibodies", "Binding", "Biochemical", "Biological", "Biomedical Engineering", "Biophysics", "Blood", "Blood Platelets", "Blood Vessels", "COVID-19", "COVID-19 pandemic", "COVID-19 vaccination", "Complex", "Dangerousness", "Disease", "Disease Outcome", "Disseminated Intravascular Coagulation", "Elements", "Endothelial Cells", "Endothelium", "Engineering", "Environment", "Epitopes", "Etiology", "Genetic", "Germ Lines", "Hematologist", "Idiopathic Thrombocytopenic Purpura", "Immune", "Immunity", "In Vitro", "Innate Immune Response", "Investigation", "Link", "Mass Spectrum Analysis", "Microfluidic Microchips", "Microfluidics", "Microscopic", "Modeling", "Molecular", "Monitor", "Monoclonal Antibodies", "Mutation", "N-Glycosylation Site", "Neutrophil Activation", "PF4 Gene", "Pathogenesis", "Pathogenicity", "Pathology", "Patients", "Phenotype", "Physiological", "Platelet Activation", "Polymers", "Polysaccharides", "Predisposition", "Property", "Proteins", "Recombinants", "Research", "Research Personnel", "Role", "Signal Transduction", "Stroke", "Surface", "Techniques", "Therapeutic", "Thrombocytopenia", "Thrombosis", "Thrombus", "Universities", "Vaccination", "Vaccines", "Variant", "Work", "antigen binding", "biophysical tools", "cerebral vein", "chemokine", "crosslink", "delivery vehicle", "design", "genetic predictors", "global health", "glycosylation", "hemodynamics", "immunothrombosis", "in vitro Model", "individual patient", "medical schools", "novel", "pathogen", "physical property", "preservation", "prevent", "prophylactic", "rational design", "recruit", "shear stress", "side effect", "stoichiometry", "thrombogenesis", "thrombotic", "tool", "vaccine trial", "vector vaccine", "venous sinus" ], "approved": true } }, { "type": "Grant", "id": "15713", "attributes": { "award_id": "1R01HL178459-01", "title": "Novel cysteinyl leukotriene receptor signaling in regulating cellular, and molecular events in lung inflammation", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Heart Lung and Blood Institute (NHLBI)" ], "program_reference_codes": [], "program_officials": [ { "id": 32586, "first_name": "ROYA", "last_name": "KALANTARI", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2025-06-09", "end_date": "2029-02-28", "award_amount": 579309, "principal_investigator": { "id": 32587, "first_name": "Sailaja", "last_name": "Paruchuri", "orcid": "", "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 823, "ror": "", "name": "UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS", "address": "", "city": "", "state": "OH", "zip": "", "country": "United States", "approved": true }, "abstract": "Project summary: Cysteinyl leukotrienes (cys-LTs; LTC4, LTD4, and LTE4) play an important role in asthma, allergy, and inflammatory bowel diseases via their receptors, CysLT1R and CysLT2R. However, the role of cys-LTs in regulating the inflammatory and proliferative phenotypes of macrophages (MФ) or their role in MФ-mediated lung inflammation is not well defined. Our preliminary work revealed a previously unidentified role for CysLT1R in balancing MФs’ inflammatory potential, metabolic function, and proliferation in vitro, and a role in driving LPS- mediated lung inflammation in vivo. Based on these findings, we hypothesize that the presence of CysLT1R drives the inflammatory state of MФs and lung inflammation in response to LPS. Further, since CysLT1R and CysLT2R antagonize each other, CysLT1R may act as a molecular brake for MФ hyper-proliferation via binding to and inhibiting CysLT2R. We propose to test this hypothesis in three aims. In Aim 1, we will determine the mechanistic aspects of how CysLT1R promotes the hyper-inflammatory MФ phenotype in vitro and analyze how CysLT1R influences the resident and recruited immune population in the lung in response to acute lung injury (ALI). In Aim 2, we will elucidate how CysLT1R suppresses MФ proliferation, and metabolism, and we will explore its antagonism towards CysLT2R in deciding the MФ activation state. Finally, in Aim 3, we will determine the pathophysiological significance of myeloid CysLT1R signaling in mediating lung inflammation in murine ALI models. Further, we will explore the therapeutic potential of blocking CysLT1R using MK571/Singulair, an FDA- approved asthma drug. Although a few reports have suggested the benefits of Singulair in reducing pulmonary inflammation during LPS-ALI and COVID-19, neither the mechanistic aspects, nor its prophylaxis vs therapeutic effect on all ALI parameters, were previously addressed. The successful completion of our project will unravel the previously unknown unique roles of CysLTR in influencing MФ function and its role in lung inflammation/injury.", "keywords": [ "Acute Lung Injury", "Acute Respiratory Distress Syndrome", "Address", "Affect", "Agonist", "American", "Arachidonic Acids", "Arbitration", "Asthma", "Autocrine Communication", "Automobile Driving", "Binding", "Biology", "Biophysics", "COVID-19", "Cells", "Clinical", "Death Rate", "Disease", "Endothelium", "Equilibrium", "Event", "Exhibits", "FDA approved", "G-Protein-Coupled Receptors", "Genes", "Hypersensitivity", "Immune", "Impairment", "In Vitro", "Infection", "Inflammation", "Inflammatory", "Inflammatory Bowel Diseases", "Inflammatory Response", "Injury", "Knock-out", "Knockout Mice", "Knowledge", "Laboratories", "Leukotriene C4", "Leukotriene D4", "Leukotriene E4", "Leukotrienes", "Life", "Lipids", "LoxP-flanked allele", "Lung", "Lung Diseases", "Macrophage", "Macrophage Activation", "Mediating", "Metabolic", "Metabolism", "Modeling", "Molecular", "Morbidity - disease rate", "Mus", "Myelogenous", "Myeloid Cells", "Organ", "Outcome", "Patients", "Pharmaceutical Preparations", "Phenotype", "Play", "Pneumonia", "Population", "Positioning Attribute", "Production", "Proliferating", "Prophylactic treatment", "Pulmonary Inflammation", "Receptor Signaling", "Refractory", "Regulation", "Reporting", "Research", "Resolution", "Respiratory Failure", "Role", "Sepsis", "Signal Transduction", "Supportive care", "Testing", "Therapeutic", "Therapeutic Effect", "Tissues", "Trachea", "Urine", "Vascular Permeabilities", "Wild Type Mouse", "Work", "antagonist", "aspirate", "cecal ligation puncture", "clinical efficacy", "cysteinyl leukotriene receptor", "cysteinyl-leukotriene", "cytokine", "cytokine release syndrome", "effective therapy", "endothelial dysfunction", "experience", "experimental study", "functional outcomes", "immunogenic", "improved", "in vivo", "inhibitor", "insight", "lipid mediator", "lung injury", "mortality", "neutrophil", "novel", "novel therapeutic intervention", "novel therapeutics", "prevent", "receptor", "recruit", "response", "restraint", "treatment strategy" ], "approved": true } }, { "type": "Grant", "id": "14583", "attributes": { "award_id": "1R25AI181750-01", "title": "HBCU/MSI Mentored Research Program in the Structural Biology of Human Pathogens", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Allergy and Infectious Diseases (NIAID)" ], "program_reference_codes": [], "program_officials": [ { "id": 31247, "first_name": "MADELYN", "last_name": "Reyes", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-05-08", "end_date": "2029-03-31", "award_amount": 339012, "principal_investigator": { "id": 31248, "first_name": "Jamaine S", "last_name": "Davis", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 938, "ror": "https://ror.org/00k63dq23", "name": "Meharry Medical College", "address": "", "city": "", "state": "TN", "zip": "", "country": "United States", "approved": true }, "abstract": "Meharry Medical College is continuing its mission in training underrepresented minority students for diseases that disproportionately impact underserved communities. As the COVID-19 pandemic has highlighted, infectious diseases continue to cause a global humanitarian and economic burden. The most effective way to combat the continued emergence of infectious diseases is to have a robust drug development pipeline at the ready. The training for scientists in this drug development pipeline to combat infectious diseases needs to include structural biology and students traditionally underrepresented in biomedical sciences. To strengthen professional and scientific skills to enhance scientific productivity, particularly in the field of structural biology of human pathogens, novel programs, such as the one proposed are needed. The proposed HBCU/MSI Mentored Research Program in the Structural Biology of Human Pathogens is a 10- week summer program will provide an intensive, hands-on research experience for students (community college, undergraduate, medical) that will deliver training and education in the structural biology of infectious disease proteins. Research training will be provided by a diverse faculty consisting of experienced structural biology investigators from Meharry Medical College and Vanderbilt University Medical Center. A nationwide search will be conducted to select 10-16 students per year who are interested in pursuing careers in medicine and biomedical science related to NIAID. Student research projects will focus on structures on human pathogens, provide by our partnership with Seattle Structural Genomics Center for Infectious Diseases (SSGCID). Student education will encompass the fundamentals of structural biology provided in a mini-course and mentored through the solving of protein structures. This exciting and innovative program will give each student participant the full workflow of solving a protein structure from prediction to expression all the way through to structure determination and publication. As a collaborator, Black In Biophysics will assign a Career Mentor to each participant and students will participate in career development workshops to explore career options, create individual development plans, and obtain information needed to apply and successfully gain entrance into Ph.D. and M.D. training programs. At the end of the 10-week program, students will have an opportunity to create oral and poster presentations describing their research and present their research findings internally during the Summer Research Symposium and externally at one national conference. Program directors and staff will track participants through their undergraduate/medical and post graduate training to evaluate the extent to which program goals were met and identify areas for improvement. Evaluations from research mentors and program directors/chairs will also be used to assess and improve the program.", "keywords": [ "3-Dimensional", "Academia", "Academic Medical Centers", "Area", "Authorship", "Biomedical Research", "Biophysics", "Black race", "COVID-19", "COVID-19 impact", "COVID-19 pandemic", "Cessation of life", "Communicable Diseases", "Computer software", "Crystallization", "Data", "Data Collection", "Development", "Development Plans", "Disease", "Doctor of Medicine", "Doctor of Philosophy", "Economic Burden", "Education", "Educational process of instructing", "Educational workshop", "Ethnic Population", "Evaluation Research", "Faculty", "Funding", "Genomic Centers for Infectious Diseases", "Global Awareness", "Goals", "Historically Black Colleges and Universities", "Individual", "Industry", "Infectious Agent", "Journals", "Medical", "Medicine", "Mentors", "Mentorship", "Microbiology", "Mission", "National Institute of Allergy and Infectious Disease", "Oral", "Participant", "Play", "Production", "Productivity", "Program Evaluation", "Protein Biochemistry", "Proteins", "Protocols documentation", "Public Health", "Publications", "Publishing", "Research", "Research Personnel", "Research Project Grants", "Research Training", "Roentgen Rays", "Schools", "Science", "Science Technology Engineering and Mathematics", "Scientist", "Societies", "Structural Biochemistry", "Structural Biologist", "Structure", "Students", "Therapeutic", "Training", "Training Programs", "Training and Education", "Underrepresented Minority", "Work", "X-Ray Crystallography", "career", "career development", "combat", "community college", "course development", "data structure", "design", "drug development", "experience", "future outbreak", "hands on research", "human pathogen", "improved", "innovation", "interest", "lectures", "medical schools", "member", "next generation", "novel", "novel therapeutics", "posters", "prevent", "programs", "protein structure", "protein structure prediction", "racial population", "recruit", "skills", "structural biology", "structural genomics", "summer program", "summer research", "symposium", "three dimensional structure", "undergraduate student", "underrepresented minority student", "underserved community", "virtual", "virtual platform" ], "approved": true } }, { "type": "Grant", "id": "14597", "attributes": { "award_id": "1K23NS133488-01A1", "title": "Magnetic Resonance Imaging Biomarkers of Post-COVID-19 Cerebral Microvascular Dysfunction", "funder": { "id": 4, "ror": "https://ror.org/01cwqze88", "name": "National Institutes of Health", "approved": true }, "funder_divisions": [ "National Institute of Neurological Disorders and Stroke (NINDS)" ], "program_reference_codes": [], "program_officials": [ { "id": 6896, "first_name": "WILLIAM PATRICK", "last_name": "Daley", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] } ], "start_date": "2024-05-15", "end_date": "2029-03-31", "award_amount": 231524, "principal_investigator": { "id": 31268, "first_name": "Lindsay", "last_name": "McAlpine", "orcid": null, "emails": "", "private_emails": "", "keywords": null, "approved": true, "websites": null, "desired_collaboration": null, "comments": null, "affiliations": [] }, "other_investigators": [], "awardee_organization": { "id": 452, "ror": "https://ror.org/03v76x132", "name": "Yale University", "address": "", "city": "", "state": "CT", "zip": "", "country": "United States", "approved": true }, "abstract": "Neurologic post-acute sequelae of SARS-CoV-2 infection (neuro-PASC) is a pressing public health issue and little is known about the cause, duration, and potential treatments. It is defined as a new health problem occurring three months after initial COVID infection and lasting for at least two months. Common symptoms of neuro- PASC include headache, inattention, cognitive impairment, dizziness, insomnia, and mood changes. Emerging evidence suggests that persistent microvascular inflammation and dysfunction play critical roles in the PASC of the lungs and heart. Numerous post-mortem studies have demonstrated significant microvascular damage and dysfunction in the brains of individuals who have died of acute COVID-19. In the brains of individuals living with neuro-PASC, case-control studies have found microvascular dysfunction, cerebral hypoperfusion, and new small vessel disease. The long-term neurologic effects of microvascular dysfunction and subsequent risk of vascular dementia is unknown. I hypothesize that cerebral microvascular dysfunction plays a critical role in neuro- PASC cognitive impairment and puts individuals at risk for progression of small vessel disease. Here, I propose utilizing advanced vascular MRI techniques to investigate for biomarkers of microvascular dysfunction in the brain to better understand the pathophysiology of neuro-PASC and risk for progression of small vessel disease. Understanding the underlying disease process will bring us closer to identifying biomarkers and treatment targets. In order to enrich the probability of finding MRI alterations, I will recruit participants with cognitive impairment, which is the most common and well-documented neuro-PASC symptom. I will conduct a longitudinal study and perform two sets of MRIs, blood tests, and neuropsychological tests on each participant. I will recruit at least 50 adults with a documented COVID-19 infection and cognitive symptoms and compare them to 50 adults with a documented COVID-19 infection and no residual symptoms (controls). My detailed MRI protocol will evaluate the vessel wall, arterial, and venous vasculature and explore techniques to map the lymphatic vasculature. In the blood, I will test markers of coagulopathy, endotheliopathy, and neurodegeneration. I am a neurologist and physician-scientist who has developed clinical and scientific expertise in neuro-PASC through caring for patients in the NeuroCOVID Clinic at Yale, and I am working in the neuro-infectious disease laboratory of my primary mentor. I recently graduated from fellowship, and I am now an Instructor in the Department of Neurology. My long-term goal is to become an independent clinician-scientist with a focus on utilizing neuroimaging techniques to understand the pathophysiology of neuro-PASC and generate biomarkers of disease and treatment targets. To accomplish this goal, I have assembled a world class mentorship team with experts in neuroradiology, neuropsychology, and neuro-ID. I will take advanced coursework in neuroimaging, statistics, and vascular biology. The completion of this mentored award will prepare me to become an independent physician-scientist and allow me to make meaningful contributions to the field and to patient care.", "keywords": [ "Adult", "Atrophic", "Autopsy", "Award", "Biological Markers", "Biology", "Blood", "Blood Coagulation Disorders", "Blood Platelets", "Blood Tests", "Blood Vessels", "Brain", "COVID-19", "Cardiovascular system", "Case Series", "Case/Control Studies", "Cerebrum", "Clinic", "Clinical", "Cognition", "Cognitive", "Cognitive deficits", "Data", "Diffusion", "Disease", "Dizziness", "Endothelium", "Enrollment", "Exhibits", "Fellowship", "Functional disorder", "Future", "Goals", "Headache", "Health", "Heart", "Image", "Impaired cognition", "Individual", "Inflammatory", "Ischemic Stroke", "Laboratories", "Language", "Link", "Long-Term Effects", "Longitudinal Studies", "Lung", "Lymph Node Mapping", "Magnetic Resonance Imaging", "Memory", "Mental Health", "Mentors", "Mentorship", "Microvascular Dysfunction", "Mind", "Moods", "Morbidity - disease rate", "Motor", "Nerve Degeneration", "Neurobehavioral Manifestations", "Neurologic Effect", "Neurologist", "Neurology", "Neuropsychological Tests", "Neuropsychology", "Participant", "Pathology", "Patient Care", "Patient Recruitments", "Patients", "Perception", "Perfusion", "Persons", "Physicians", "Pilot Projects", "Play", "Post-Acute Sequelae of SARS-CoV-2 Infection", "Probability", "Process", "Protocols documentation", "Public Health", "Publishing", "Reporting", "Residual state", "Risk", "Role", "SARS-CoV-2 infection", "Scientist", "Severities", "Short-Term Memory", "Sleeplessness", "Symptoms", "Techniques", "Testing", "Time", "Training", "Vascular Dementia", "Vascular Diseases", "Venous", "Visit", "acute COVID-19", "biomarker identification", "cerebral hypoperfusion", "common symptom", "comparison control", "endothelial dysfunction", "high risk", "hypoperfusion", "inattention", "insight", "instructor", "lymphatic vasculature", "magnetic resonance imaging biomarker", "mortality", "neuroimaging", "neurologic sequelae of COVID-19", "neuropsychiatry", "post-COVID-19", "primary outcome", "progression risk", "recruit", "research study", "statistics", "vascular inflammation" ], "approved": true } } ], "meta": { "pagination": { "page": 1392, "pages": 1424, "count": 14236 } } }